The goal of this activity is for learners to be better able to describe long-term outcome data for patients with CLL treated in the multicenter, randomized, phase 3 Alliance for Clinical Trials in Oncology study (A041202), based on the protocol-planned third interim analysis of progression free survival (PFS) for ibrutinib (I) and ibrutinib plus rituximab (IR) versus bendamustine plus rituximab (BR), and second planned interim analysis of I versus IR in 547 eligible patients.
- Provider:Medscape, LLC
- Activity Link: https://www.medscape.org/viewarticle/1000679
- Start Date: 2024-04-18 05:00:00
- End Date: 2024-04-18 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
- MOC Credit Details: ABIM - 1.0 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: No
- Activity Type: Journal-based CE
- CME Finder Type: Other
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Jointly Provided
- Registration: Open to all
- Specialty: Cardiovascular Disease, Hematology, Internal Medicine
Subscribe
Login
0 Comments
Oldest